An anti-platelet medication used to prevent stroke and heart attack in people with vascular risk factors.
Drug Class: cardiovascular
Aspirin is an anti-platelet medication that helps prevent blood clots. In neuro-ophthalmology, it's used for vascular conditions and prevention of stroke after transient vision loss.
Key Takeaways
- Prevents blood clots
- Used after transient vision loss from vascular causes
- Part of stroke prevention
- Low dose (81 mg) usually sufficient
- Increases bleeding risk
Common Uses
- After transient vision loss (amaurosis fugax)
- After retinal artery occlusion
- Microvascular cranial nerve palsy
- Stroke prevention
- Heart disease prevention
How It Works
- Inhibits platelet clumping
- Reduces blood clot formation
- Prevents vessel blockage
- Single dose effect lasts days (platelets affected for their lifespan)
Typical Dosing
- Low dose: 81 mg daily (baby aspirin)
- Sometimes 325 mg
- Take with food to reduce stomach upset
- Consistent daily dosing important
Side Effects
Common
- Stomach upset
- Heartburn
- Easy bruising
- Minor bleeding
Serious
- GI bleeding
- Hemorrhagic stroke (rare)
- Allergic reactions
Precautions
Avoid if:
- Active GI bleeding
- Bleeding disorder
- Aspirin allergy
- Before some surgeries
Use Caution if:
- History of ulcers
- On other blood thinners
- Kidney disease
- Asthma (some people)
Drug Interactions
- Other blood thinners (increased bleeding)
- Ibuprofen (may reduce aspirin effect if taken first)
- NSAIDs (increased GI bleeding)
Important Points
- Don't stop suddenly before surgery without medical advice
- Tell all doctors and dentists you take aspirin
- Report unusual bleeding
- Prescription medications may replace aspirin for some patients
Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice.
Medically Reviewed Content
This article meets our editorial standards
- Written by:
- Hashemi Eye Care Medical Team
- Medically reviewed by:
- Board-Certified Neuro-Ophthalmologist (MD, Neuro-Ophthalmology)
- Last reviewed:
- January 30, 2025
